These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia. Katlama C; Soulié C; Caby F; Denis A; Blanc C; Schneider L; Valantin MA; Tubiana R; Kirstetter M; Valdenassi E; Nguyen T; Peytavin G; Calvez V; Marcelin AG J Antimicrob Chemother; 2016 Sep; 71(9):2646-50. PubMed ID: 27287235 [TBL] [Abstract][Full Text] [Related]
48. Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression. Revollo B; Viñuela L; de la Mora L; García F; Noguera-Julián M; Parera M; Paredes R; Llibre JM J Antimicrob Chemother; 2022 May; 77(6):1738-1740. PubMed ID: 35274144 [TBL] [Abstract][Full Text] [Related]
49. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection. Santevecchi BA; Miller S; Childs-Kean LM Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480 [TBL] [Abstract][Full Text] [Related]
50. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial. Kintu K; Malaba TR; Nakibuka J; Papamichael C; Colbers A; Byrne K; Seden K; Hodel EM; Chen T; Twimukye A; Byamugisha J; Reynolds H; Watson V; Burger D; Wang D; Waitt C; Taegtmeyer M; Orrell C; Lamorde M; Myer L; Khoo S; Lancet HIV; 2020 May; 7(5):e332-e339. PubMed ID: 32386721 [TBL] [Abstract][Full Text] [Related]
51. Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients. Radford M; Parks DC; Ferrante S; Punekar Y AIDS; 2019 Sep; 33(11):1739-1749. PubMed ID: 31180906 [TBL] [Abstract][Full Text] [Related]
52. Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation. Braun DL; Scheier T; Ledermann U; Flepp M; Metzner KJ; Böni J; Günthard HF Viruses; 2020 Nov; 12(11):. PubMed ID: 33228206 [TBL] [Abstract][Full Text] [Related]
53. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing. Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D; BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115 [TBL] [Abstract][Full Text] [Related]
54. Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results. Oldenbuettel C; Wolf E; Ritter A; Noe S; Heldwein S; Pascucci R; Wiese C; Von Krosigk A; Jaegel-Guedes E; Jaeger H; Balogh A; Koegl C; Spinner CD Antivir Ther; 2017; 22(2):169-172. PubMed ID: 27588613 [TBL] [Abstract][Full Text] [Related]
55. Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals. Negredo E; Estrada V; Domingo P; Gutiérrez MD; Mateo GM; Puig J; Bonjoch A; Ornelas A; Echeverría P; Estany C; Toro J; Clotet B J Antimicrob Chemother; 2017 Mar; 72(3):844-849. PubMed ID: 27999056 [TBL] [Abstract][Full Text] [Related]
56. Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). Di Giambenedetto S; Fabbiani M; Quiros Roldan E; Latini A; D'Ettorre G; Antinori A; Castagna A; Orofino G; Francisci D; Chinello P; Madeddu G; Grima P; Rusconi S; Di Pietro M; Mondi A; Ciccarelli N; Borghetti A; Focà E; Colafigli M; De Luca A; Cauda R; J Antimicrob Chemother; 2017 Apr; 72(4):1163-1171. PubMed ID: 28093483 [TBL] [Abstract][Full Text] [Related]
57. Dolutegravir plus lamivudine dual therapy - a new option for initial antiretroviral therapy. Fida M; Rizza SA; Temesgen Z Drugs Today (Barc); 2019 May; 55(5):297-304. PubMed ID: 31131840 [TBL] [Abstract][Full Text] [Related]
58. HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir + lamivudine in the maintenance DOLULAM pilot study. Charpentier C; Montes B; Perrier M; Meftah N; Reynes J J Antimicrob Chemother; 2017 Oct; 72(10):2831-2836. PubMed ID: 29091218 [TBL] [Abstract][Full Text] [Related]
59. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Cahn P; Andrade-Villanueva J; Arribas JR; Gatell JM; Lama JR; Norton M; Patterson P; Sierra Madero J; Sued O; Figueroa MI; Rolon MJ; Lancet Infect Dis; 2014 Jul; 14(7):572-80. PubMed ID: 24783988 [TBL] [Abstract][Full Text] [Related]
60. Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus. Navarro J; Santos JR; Silva A; Burgos J; Falcó V; Ribera E; Imaz A; Curran A Pharmacotherapy; 2019 Apr; 39(4):501-507. PubMed ID: 30723941 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]